RefleXion Announces Licensing Agreement with Mirada Medical to Advance Personalized Cancer Treatment
Retrieved on:
Thursday, July 7, 2022
Technology, Medical Devices, Hospitals, Photography, Software, Biotechnology, Other Health, Health, Oncology, Patient, CEO, Biology, Reflection, Â, Anatomy, Melcher, Cancer, Industry, Radiation, Positron, CT, SBRT, Neoplasm, PET, Toxicity, Software, IMRT, Mirada Studios, SRS, Digestion, Time, Algorithm, Medical imaging, Control
RefleXion Medical , a therapeutic oncology company pioneering the use of biology-guided radiotherapy ( BgRT )* for all stages of cancer, today announced a non-exclusive, worldwide licensing agreement with Mirada Medical .
Key Points:
- RefleXion Medical , a therapeutic oncology company pioneering the use of biology-guided radiotherapy ( BgRT )* for all stages of cancer, today announced a non-exclusive, worldwide licensing agreement with Mirada Medical .
- The agreement allows for the integration of Miradas RegEngine image registration algorithms into the RefleXion X1 treatment planning software.
- Miradas extensive industry experience and development expertise were key factors in our decision to pursue this agreement, continued Melcher.
- Mirada Medical specializes in simplifying technically complex image processing tasks, allowing clinicians to diagnose disease, assess response to treatment, and plan radiation therapy or surgical intervention more confidently.